摘要
Blincyto(药物名Blinatumomab)用于治疗复发性或难治性B细胞淋巴瘤,应用期间不良反应较多但均可耐受。本文回顾了2018年1月-2019年8月应用Blincyto联合化疗治疗复发性或难治性B细胞淋巴瘤11例的临床资料,共有8(72.73%)例患者发生药物相关不良反应,其中发热3(27.27%)例、疼痛2(18.18%)例、疲倦2(18.18%)例、腹泻1(9.09%)例,经处理后均缓解并且顺利完成治疗。本文总结应用Blincyto治疗的过程中的保存、药物配置方法、输注要点、不良反应等要点,旨在为患者提供规范的护理措施依据。
Objective The Blinatumomab(Blincyto~?)is the single-agent immunotherapy to treat the relapsed or refractory B-cell malignancies.It has sound curative effect with tolerable adverse reactions.This paper retrospectively analyzed the clinical data of 11 patients receiving Blinatumomab for relapsed or refractory B-cell malignancies.Totally 8(72.73%)cases of drug adverse reactions were found,including 3 cases of fever,2 cases of pain,2 cases of fatigue and 1 case of diarrhea.This paper also summarized the nursing management during the period of Blinatumomab treatment form the perspectives of drug preservation,medicine disposition,precautions in infusion and adverse reactions,in order to provide reference for standardized nursing management.
作者
曾秀娟
彭丽娟
黄旭霞
ZENG Xiujuan;PENG Lijuan;HUANG Xuxia(Department of Chemotherapy,Sun Yet-Sen University Cancer Center,Guangzhou,Guangdong,510060)
出处
《中西医结合护理（中英文）》
2020年第5期147-149,共3页
Journal of Clinical Nursing in Practice
关键词
化疗
免疫疗法
B细胞淋巴瘤
不良反应
chemotherapy
immunotherapy
B-cell malignancy
adverse reaction
